Market Update (NASDAQ:AMGN): Amgen wins EU green light for first virus-based cancer drug

[Reuters] – A first-in-class drug from Amgen based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months. . . . → Read More: Market Update (NASDAQ:AMGN): Amgen wins EU green light for first virus-based cancer drug Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen wins first approval for new class of cholesterol drugs Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week